Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against CTO Realty Growth, Inc. due to allegations of misleading statements regarding the sustainability of dividends and financial practices, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 7, 2025 [1][3][6]. Group 1: Allegations Against CTO - The complaint alleges that CTO and its executives violated federal securities laws by making false and misleading statements about the sustainability of dividends and the true profitability of its Ashford Lane property [3]. - The Wolfpack Research report claims CTO has not generated enough cash to cover its recurring capital expenditures and dividends since converting to a REIT in 2021, relying on share dilution to cover a $38 million dividend shortfall from 2021 to 2024 [4]. - The report also accuses CTO of using a manipulative definition of Adjusted Funds From Operations (AFFO) and hiding financial issues related to a major tenant at Ashford Lane [4]. Group 2: Financial Impact - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98 per share, or 5.42%, closing at $17.10 per share on June 25, 2025 [5]. - CTO is reported to have only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, indicating potential financial strain [4]. Group 3: Legal Proceedings - Investors who purchased CTO securities between February 18, 2021, and June 24, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding CTO's conduct [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Tronox Holdings plc due to significant financial losses and misleading statements made by the company regarding its performance and outlook [4][6]. Group 1: Company Performance - Tronox reported a significant reduction in TiO2 sales for Q2 2025, attributing the decline to a softer coatings season and increased competition [7]. - Following the disappointing sales results, Tronox revised its full-year revenue guidance downward and cut its dividend by 60% [7]. - The company's stock price plummeted from $5.14 per share on July 30, 2025, to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in just one day [8]. Group 2: Legal Actions - Investors who suffered losses exceeding $75,000 in Tronox between February 2, 2025, and July 30, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1]. - A federal securities class action has been filed against Tronox, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [4][9]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Tronox's conduct [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sable Offshore Corp. due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's oil production activities [4][6]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Sable Offshore, with a deadline of September 26, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Sable Offshore and its executives made false statements about the company's oil production restart, which had not occurred [6][7]. - Investors who suffered losses between May 19, 2025, and June 3, 2025, are encouraged to contact the law firm to discuss their legal rights [1][4]. Group 2: Stock Performance and Market Reaction - Following a court injunction against Sable's pipeline activities, the company's stock fell by $5.04 per share, or 15.3%, closing at $27.89 on May 28, 2025 [7]. - The injunction was granted by the California Coastal Commission, raising concerns about potential project delays and additional costs for Sable Offshore [7]. Group 3: Firm Background and Recovery - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [5]. - The firm is actively seeking information from whistleblowers, former employees, and shareholders regarding Sable Offshore's conduct [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PubMatic, Inc. due to allegations of misleading statements and failure to disclose significant changes affecting the company's revenue and operations [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in PubMatic between February 27, 2025, and August 11, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 20, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against PubMatic [4][8]. Group 2: Allegations Against PubMatic - The complaint alleges that PubMatic and its executives violated federal securities laws by making false or misleading statements regarding a top DSP buyer shifting clients to a new platform, leading to reduced ad spend and revenue [6]. - Following the release of its second quarter 2025 financial report on August 11, 2025, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share due to the disclosed reduction in ad spend from a top DSP partner [7]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [5].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Fortinet, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Performance - On August 6, 2025, Fortinet reported its Q2 2025 financial results, indicating that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" based on remaining active units and service contracts [3]. - The company provided weaker than expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [3]. Stock Market Reaction - Following the financial results announcement, Fortinet's share price fell by $21.28, or approximately 22%, from $96.58 on August 6, 2025, to close at $75.30 on August 7, 2025 [4].

Core Insights - AVITA Medical, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] - The company's second quarter 2025 financial results revealed a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand [3] - AVITA's share price dropped by approximately 21% following the announcement of the backlog, from $5.38 to $4.25 per share [3] Company Overview - AVITA Medical, Inc. is involved in the development and commercialization of wound care products, specifically the Recell system [3] - The company faced challenges due to contractors from the Centers for Medicare & Medicaid Services failing to timely adjudicate claims and assign appropriate pricing for its products [3] Financial Impact - The backlog of unpaid claims accumulated from January to June 2025, leading to uncertainty among providers and a reduction in Recell utilization during the first half of the year [3] - The decline in share price reflects investor concerns regarding the company's operational challenges and financial health [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4][9]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements [6][8]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA, citing the same cGMP deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 [8]. Group 3: Company Background - Unicycive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker UNCY [4]. - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in new merchant acquisitions [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service [2]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable [2]. - The lawsuit contends that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans, with a deadline for investors to seek lead plaintiff status in a federal class action by October 10, 2025 [2][4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, rather than providing unbiased comparisons [4]. - SelectQuote is accused of receiving illegal kickbacks from health insurance companies to steer beneficiaries towards certain plans, which may have violated federal laws [4][5]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in the company's stock price by 19.2% on May 1, 2025 [5]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $75,000 in SelectQuote between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal options with Faruqi & Faruqi [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [6]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding SelectQuote's conduct [7].

Core Insights - Kirby McInerney LLP is investigating potential claims against PubMatic, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3] - PubMatic reported a significant revenue decline expected in Q3 2025 due to reduced ad spend from a major demand-side platform (DSP) partner [3] Financial Performance - On August 11, 2025, PubMatic disclosed a headwind from a top DSP buyer that shifted clients to a new platform, impacting revenue [3] - Following the announcement, PubMatic's share price fell by $2.23, approximately 21.1%, from $10.57 to $8.34 [3]